Drug intelligence / Profile preview

Piminxiao Capsule

Development stage: Unknown
Lead developer: Sichuan Defeit Pharmaceutical
Administration: Oral

Overview

Piminxiao Capsule is a traditional Chinese medicine (TCM) formulation developed by the Jiangsu Province Hospital of Chinese Medicine for the treatment of chronic spontaneous urticaria (CSU). It is specifically indicated for patients presenting with the TCM syndromes of 'wind-heat' or 'wind-heat with dampness.' The capsule is typically used as an adjunctive therapy alongside second-generation H1-antihistamines, such as levocetirizine, to enhance therapeutic efficacy, reduce the Urticaria Activity Score (UAS7), and lower the rate of recurrence. As a botanical product, its pharmacological profile involves multi-target anti-inflammatory and immunomodulatory effects characteristic of its constituent herbs.

Brand names: Piminxiao Capsule
Other names: Pimin Xiao CapsulePimin Xiao Jiaonang

Beyond the preview

Go deeper on Piminxiao Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Piminxiao Capsule.

Explore the full profile